Honghao Fang, PhD

Associate
Analysis Group, United Kingdom

Poster(s):

• (360) Real-World Clinical Outcomes and Disease Management Costs among High-Risk Non-Muscle Invasive Bladder Cancer Patients Treated with Bacillus Calmette-Guérin: A SEER-Medicare Analysis
  Wednesday, October 29, 2025

• (385) Real-world treatment history and economic outcomes of CD38 antibody-based regimens in relapsed/refractory multiple myeloma in the United States
  Wednesday, October 29, 2025